LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $105.80.

LMAT has been the subject of a number of recent research reports. Roth Mkm reissued a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research report on Tuesday. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st.

Insider Buying and Selling

In other news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the transaction, the insider directly owned 6,677 shares in the company, valued at approximately $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Roberts sold 8,464 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the transaction, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 215,438 shares of company stock worth $23,062,911 in the last 90 days. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the stock. M&T Bank Corp raised its position in shares of LeMaitre Vascular by 2,240.5% during the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock worth $32,283,000 after purchasing an additional 381,061 shares during the period. Goldman Sachs Group Inc. grew its position in shares of LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after purchasing an additional 231,157 shares during the period. First Trust Advisors LP grew its position in shares of LeMaitre Vascular by 35.4% in the 3rd quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock valued at $72,541,000 after purchasing an additional 216,919 shares during the period. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after purchasing an additional 105,921 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Down 0.2%

LeMaitre Vascular stock opened at $108.49 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $115.33. The firm has a fifty day moving average price of $98.67 and a two-hundred day moving average price of $90.56. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of 43.22, a P/E/G ratio of 3.13 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the previous year, the business posted $0.49 EPS. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were paid a $0.25 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular’s payout ratio is presently 39.84%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.